Hemostatic performance and biocompatibility of chitosan-based agents in experimental parenchymal bleeding.

The uncontrolled parenchymatic bleeding is still a cause of serious complications in surgery and require new effective hemostatic materials. In recent years, numerous chitosan-based materials have been intensively studied for parenchymatic bleeding control but still require to increased safety and effectiveness. The current research is devoted to new hemostatic materials made of natural polymer (chitosan) developed using electrospinning and microwave-assisted methods. Hemostatic performance, biocompatibility, degradation, and in-vivo effectiveness were studied to assess functional properties of new materials. Chitosan-based agents demonstrated considerable hemostatic performance, moderate biodegradation pace and high biocompatibility in vitro. Using the electrospinning-made chitosan-copolymer significantly improved in vivo biocompatibility and degradation of Chitosan-based agents that provides opportunities for its implementation for visceral bleeding management. Chitosan aerogel could be effectively applied in hemostatic patch development due to high antibacterial activity but it is not recommended for visceral application due to moderate inflammatory effect and slow degradation.

[The treatment experience of rheumatoid arthritis patients in an industrial region of the Donets Basin]. / Dosvid likuvannia khvorykh na revmatoïdnyi artryt v umovakh promyslovoho rehionu Donbasu.

The data submitted suggest that the most effective option in the treatment of rheumatoid arthritis is simultaneous employment of a nonsteroidal anti-inflammatory agent and metatrexate for 1.5 yr and courses of hormonotherapy, exercise therapy, and topical application to the joints of compresses with dimexide, heparin, and analginum as required and ultrasound with hydrocortisone as well. There was no increase in disability rates among patients with rheumatoid arthritis placed on the above combined treatment, which fact is also related to improvement of diagnosis rheumatoid arthritis, well-timed case follow-up, and prescription of courses of prophylactic treatment.